63. Idiopathic thrombocytopenic purpura Clinical trials / Disease details
Clinical trials : 391 / Drugs : 235 - (DrugBank : 50) / Drug target genes : 49 - Drug target pathways : 139
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05325593 (ClinicalTrials.gov) | December 2, 2022 | 7/3/2022 | Romiplostim Plus Dexamethasone vs Dexamethasone in Patients With Newly Diagnosed Primary Immune Thrombocytopenia | A Multicentre, Randomized, Open-label Study of Romiplostim Plus Dexamethasone vs Dexamethasone in Patients With Newly Diagnosed Primary Immune Thrombocytopenia | Primary Immune Thrombocytopenia | Drug: romiplostim plus dexamethasone;Drug: Dexamethasone | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | NULL | Recruiting | 18 Years | N/A | All | 126 | Phase 3 | Spain |